



Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14875-151US1	Application No. 10/550,934
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Masayuki Tsuchiya et al.	
		Filing Date September 28, 2005	Group Art Unit

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
/AMG/	AA	6,183,744	02/06/2001	Goldenberg			
/AMG/	AB	6,368,596	04/09/2002	Ghetie et al.			
/AMG/	AC	2003/0148409	08/07/2003	Rossi et al.			

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
/AMG/	AD	JP 10-505231	05/26/1998	Japan			see AG	
	AE	JP 2001-518930	10/16/2001	Japan			see AH	
	AF	JP 2002-544173	12/24/2002	Japan			see AI	
	AG	WO 96/04925	02/22/1996	WIPO				
	AH	WO 98/42378	10/01/1998	WIPO				
	AI	WO 00/67795	11/16/2000	WIPO				
	AJ	WO 01/74388	10/11/2001	WIPO				
	AK	WO 01/97858	12/27/2001	WIPO				
	AL	WO 02/04021	01/17/2002	WIPO				
	AM	WO 02/22212	03/21/2002	WIPO				
	AN	WO 03/033654	04/24/2003	WIPO				
/AMG/	AO	WO 03/104425	12/18/2003	WIPO				

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
/AMG/	AP	Fayen et al., "Negative signaling by anti-HLA class I antibodies is dependent upon two triggering events," <i>Int. Immunol.</i> , 10:1347-1358 (1998)
	AQ	Funaro et al., "Monoclonal antibodies and therapy of human cancers," <i>Biotechnol. Adv.</i> , 18:385-401 (2000)
	AR	Genestier et al., "Fas-Independent Apoptosis of Activated T Cells Induced by Antibodies to the HLA Class I $\alpha 1$ Domain," <i>Blood</i> , 90:3629-3639 (1997)
	AS	Holliger et al., "'Diabodies': Small bivalent and bispecific antibody fragments," <i>Proc. Natl. Acad. Sci. USA</i> , 90:6444-6448 (1993)
/AMG/	AT	Hu et al., "Minibody: A Novel Engineered Anti-Carcinoembryonic Antigen Antibody Fragment (Single-Chain Fv-CH ₃) Which Exhibits Rapid, High-Level Targeting of Xenografts," <i>Cancer Res.</i> , 56:3055-3061 (1996)

Examiner Signature /Anne M. Gussow/	Date Considered 05/28/2008
--	-------------------------------

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14875-151US1	Application No. 10/550,934
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Masayuki Tsuchiya et al.	
		Filing Date September 28, 2005	Group Art Unit

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
/AMG/	AU	Kreitman et al., "Cytotoxic Activity of Disulfide-stabilized Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) toward Fresh Malignant Cells from Patients with B-Cell Leukemias," <i>Clin. Cancer Res.</i> , 6:1476-1487 (2000)
↓	AV	Matsuoka et al., "A Novel Type of Cell Death of Lymphocytes Induced by a Monoclonal Antibody without Participation of Complement," <i>J. Exp. Med.</i> , 181:2007-2015 (1995)
↓	AW	Ohtomo et al., "Molecular Cloning and Characterization of a Surface Antigen Preferentially Overexpressed on Multiple Myeloma Cells," <i>Biochem. Biophys. Res. Commun.</i> , 258:583-591 (1999)
↓	AX	Ono et al., "The humanized anti-HM1.24 antibody effectively kills multiple myeloma cells by human effector cell-mediated cytotoxicity," <i>Mol. Immunol.</i> , 36:387-395 (1999)
/AMG/	AY	Ozaki et al., "Humanized Anti-HM1.24 Antibody Mediates Myeloma Cell Cytotoxicity That Is Enhanced by Cytokine Stimulation of Effector Cells," <i>Blood</i> , 93:3922-3930 (1999)

Examiner Signature /Anne M. Gussow/	Date Considered 05/28/2008
--	-------------------------------

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.